神経変性疾患の世界市場レポート2025年

神経変性疾患市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.2％で、812億3,000万米ドルに成長します。このような成長が見込まれる背景には、遺伝子・細胞治療の進歩、デジタルバイオマーカーの利用拡大、精密医療戦略の台頭、疾患修飾薬のパイプラインの拡大、神経学における人工知能の採用拡大などがあります。予測期間中に予想される注目すべき動向には、神経画像技術の進歩、脳をターゲットとした先進ドラッグデリバリーシステム、個別化治療の革新、バイオマーカー発見の飛躍的進歩、遺伝子編集技術の進歩などがあります。

調査や臨床試験の増加は、今後の神経変性疾患市場の成長を促進すると予想されます。臨床試験とは、新しい治療法、医薬品、医療機器の安全性、有効性、潜在的な副作用を評価するために、ヒトを対象として実施される調査研究を指します。研究と臨床試験の増加は、主に、進化するヘルスケアニーズに対応し、患者の転帰を向上させるための新しい治療に対する需要の高まりによってもたらされています。これらの臨床試験は、新しい治療法の安全性と有効性に関する重要なデータを作成することにより、研究において重要な役割を果たし、それによって治療法の開発を進め、患者の治療を改善します。例えば、2023年11月、英国を拠点とする協会である英国製薬工業協会（ABPI）が発表した報告書によると、英国で毎年開始される業界の臨床試験の総数は、2021年の394試験から2022年には411試験と、4.3％の微増となりました。そのため、調査と臨床試験の増加が神経変性疾患市場の成長を促進すると予想されます。

神経変性疾患市場で事業を展開する主要企業は、治療精度の向上、疾患修飾効果の強化、患者のQOLの向上を目指し、次世代適応型深部脳刺激（aDBS）システムなどの革新的な製品の開発に注力しています。次世代適応型脳深部刺激（aDBS）システムは、神経フィードバックに基づいて刺激パラメーターを動的に調整することで、パーキンソン病の治療をリアルタイムで個別化できるように設計された先進的な神経刺激装置です。これにより治療効果が最適化され、副作用が最小限に抑えられるため、患者の転帰が改善されます。例えば、2025年2月、米国の医療技術企業であるメドトロニック社は、パーキンソン病に対する世界初の適応型脳深部刺激（aDBS）システムの承認を米国食品医薬品局（USFDA）から取得しました。今回の承認は、患者の脳信号に応じて自動的に治療を調整するブレインセンス技術を搭載した神経刺激装置Percept RCの市販前承認（PMA）申請に適用されます。このシステムは、進行したパーキンソン病患者の症状を緩和することが臨床的に検証されており、個別化神経調節療法における大きな進歩を意味します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の神経変性疾患：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の神経変性疾患市場：成長率分析
• 世界の神経変性疾患市場の実績：規模と成長, 2019-2024
• 世界の神経変性疾患市場の予測：規模と成長, 2024-2029, 2034F
• 世界の神経変性疾患：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の神経変性疾患市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• パーキンソン病
• アルツハイマー病
• 多発性硬化症
• ハンチントン病
• 筋萎縮性側索硬化症
• 世界の神経変性疾患市場：薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• N-メチル-D-アスパラギン酸受容体拮抗薬
• コリンエステラーゼ阻害剤
• ドーパミン作動薬
• 免疫調節薬
• アセチルコリンエステラーゼ（AChE）阻害剤
• 拮抗薬、モノアミン酸化酵素B（MAO-B）阻害剤
• カテコール-O-メチルトランスフェラーゼ（COMT）阻害剤
• 選択的セロトニン再取り込み阻害薬（SSRI）
• その他の薬物の種類
• 世界の神経変性疾患市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 注射剤
• 経皮
• その他の投与経路
• 世界の神経変性疾患市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の神経変性疾患市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 小売り
• オンライン
• 世界の神経変性疾患市場、パーキンソン病のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特発性パーキンソン病
• 家族性パーキンソン病
• 早期発症パーキンソン病
• パーキンソニズム
• 世界の神経変性疾患市場、アルツハイマー病のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期発症型アルツハイマー病
• 晩発性アルツハイマー病
• 家族性アルツハイマー病（FAD）
• 炎症性サブタイプ
• 非炎症性サブタイプ
• 皮質サブタイプ
• 世界の神経変性疾患市場、多発性硬化症（MS）のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床的に孤立した症候群（CIS）
• 再発寛解型多発性硬化症（RRMS）
• 二次進行性多発性硬化症（SPMS）
• 原発性進行性多発性硬化症（PPMS）
• 進行性再発性多発性硬化症（PRMS）
• 世界の神経変性疾患市場、ハンチントン病のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人発症ハンチントン病
• 若年性ハンチントン病
• 世界の神経変性疾患市場、筋萎縮性側索硬化症（ALS）のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 古典的ALS
• 四肢発症型ALS
• 球麻痺型ALS
• 呼吸器発症型ALS
• 原発性側索硬化症（PLS）
• 進行性筋萎縮症（PMA）
• 若年性ALS
• ALS-パーキンソン病-認知症複合体（ALS-PDC）

第7章 地域別・国別分析

• 世界の神経変性疾患市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の神経変性疾患市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経変性疾患市場：競合情勢
• 神経変性疾患市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Merck & Co. Inc.
• Biogen Inc.
• Neurocrine Biosciences Inc.
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Cassava Sciences Inc.
• Denali Therapeutics Inc.
• Voyager Therapeutics Inc.
• AC Immune SA
• Amylyx Pharmaceuticals Inc.
• Sage Therapeutics Inc.
• Alzheon Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 神経変性疾患市場2029：新たな機会を提供する国
• 神経変性疾患市場2029：新たな機会を提供するセグメント
• 神経変性疾患市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Neurodegenerative disease encompasses a group of disorders marked by the progressive deterioration of the structure and function of the nervous system, including the brain and spinal cord. The primary objective in this field is to understand, diagnose, and treat these conditions through advancements in biotechnology, pharmaceuticals, and medical technology. The aim is to slow disease progression, enhance patient outcomes, and lessen the burden on healthcare systems. This field also supports aging populations, improves neurological care, and contributes to a sustainable, technology-driven healthcare infrastructure.

The main types of neurodegenerative diseases include Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis. Parkinson's disease is a progressive neurological condition that impairs movement control due to the degeneration of dopamine-producing brain cells. These conditions are managed using various drug types such as N-methyl-D-aspartate (NMDA) receptor antagonists, cholinesterase inhibitors, dopamine agonists, and immunomodulatory drugs. Administration routes include oral, injectable, transdermal, and other methods. The drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. Key end-users include hospitals, retail providers, and online platforms.

The neurodegenerative diseases market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative diseases market statistics, including the neurodegenerative diseases industry global market size, regional shares, competitors with the neurodegenerative diseases market share, detailed neurodegenerative diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the neurodegenerative diseases industry. This neurodegenerative diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurodegenerative disease market size has grown strongly in recent years. It will grow from $52.30 billion in 2024 to $57.23 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. Growth in the historic period was driven by enhanced diagnostic capabilities, increased demand for symptomatic treatments, more clinical trial activity, strengthened public-private partnerships, and a growing burden of unmet medical needs.

The neurodegenerative disease market size is expected to see strong growth in the next few years. It will grow to $81.23 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. This anticipated growth is attributed to advancements in gene and cell therapy, increased use of digital biomarkers, a rise in precision medicine strategies, expansion of disease-modifying drug pipelines, and greater adoption of artificial intelligence in neurology. Notable trends expected during the forecast period include progress in neuroimaging technologies, advanced brain-targeted drug delivery systems, personalized treatment innovations, biomarker discovery breakthroughs, and advancements in gene editing techniques.

The increase in research and clinical trials is expected to propel the growth of the neurodegenerative disease market going forward. Clinical trials refer to research studies conducted with human participants to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The rise in research and clinical trials is primarily driven by the growing demand for new treatments to meet evolving healthcare needs and enhance patient outcomes. These trials play a crucial role in neurodegenerative disease research by generating essential data on the safety and effectiveness of new therapies, thereby advancing therapeutic development and improving patient care. For instance, in November 2023, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, the total number of industry clinical trials initiated annually in the UK rose slightly by 4.3%, from 394 trials in 2021 to 411 in 2022. Therefore, the increase in research and clinical trials is expected to drive the growth of the neurodegenerative disease market.

Major companies operating in the neurodegenerative disease market are focusing on developing innovative products such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, aiming to improve treatment precision, enhance disease-modifying effects, and increase patient quality of life. Next-generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation devices designed to deliver real-time, personalized treatment for Parkinson's disease by dynamically adjusting stimulation parameters based on neural feedback. This optimizes therapeutic effects and minimizes side effects, resulting in better patient outcomes. For example, in February 2025, Medtronic, a US-based medical technology company, received approval from the U.S. Food and Drug Administration (USFDA) for the world's first adaptive deep brain stimulation (aDBS) system for Parkinson's disease. This approval covers the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically adjusts therapy in response to a patient's brain signals. The system is clinically validated to provide symptom relief for advanced Parkinson's disease patients and represents a major advancement in personalized neuromodulation therapies.

In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for an undisclosed amount. Through this acquisition, AbbVie aims to advance potentially disease-modifying therapies for Alzheimer's disease and enhance its neuroscience pipeline by utilizing Aliada's innovative drug delivery platform capable of crossing the blood-brain barrier. Aliada Therapeutics is a US-based company that develops precision medicines for neurological disorders.

Major players in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

North America was the largest region in the neurodegenerative disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurodegenerative disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurodegenerative disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurodegenerative disease market consists of revenues earned by entities through services such as biotechnology research, pharmaceutical development, diagnostic solutions, medical technologies, and patient care advancements aimed at understanding, diagnosing, and treating neurodegenerative conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodegenerative disease market also includes sales of pharmaceuticals, biotechnology treatments, medical devices, and diagnostic tools aimed at managing and treating neurodegenerative conditions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurodegenerative Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurodegenerative disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurodegenerative disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurodegenerative disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Amyotrophic Lateral Sclerosis
• 2) By Drug Type: N-methyl-D-aspartate Receptor antagonists; Cholinesterase Inhibitors; Dopamine Agonists; Immunomodulatory Drugs; Acetylcholinesterase (AChE) Inhibitors; Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor; Catechol-O-Methyltransferase (COMT) Inhibitor; Selective Serotonin Reuptake Inhibitor (SSRIs); Other Drug Types
• 3) By Route of Administration: Oral; Injectable; Transdermal; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospital; Retail; Online
• Subsegment:
• 1) By Parkinson's Disease: Idiopathic Parkinson's Disease; Familial Parkinson's Disease; Early-Onset Parkinson's Disease; Parkinsonism
• 2) By Alzheimer's Disease: Early-Onset Alzheimer's Disease; Late-Onset Alzheimer's Disease; Familial Alzheimer's Disease (FAD); Inflammatory Subtype; Non-Inflammatory Subtype; Cortical Subtype
• 3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS); Relapsing-Remitting MS (RRMS); Secondary Progressive MS (SPMS); Primary Progressive MS (PPMS); Progressive-Relapsing MS (PRMS)
• 4) By Huntington's Disease: Adult-Onset Huntington's Disease; Juvenile Huntington's Disease
• 5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS; Limb-Onset ALS; Bulbar-Onset ALS; Respiratory-Onset ALS; Primary Lateral Sclerosis (PLS); Progressive Muscular Atrophy (PMA); Juvenile ALS; ALS-Parkinsonism-Dementia Complex (ALS-PDC)
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurodegenerative Disease Market Characteristics

3. Neurodegenerative Disease Market Trends And Strategies

4. Neurodegenerative Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurodegenerative Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurodegenerative Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurodegenerative Disease Market Growth Rate Analysis
• 5.4. Global Neurodegenerative Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurodegenerative Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurodegenerative Disease Total Addressable Market (TAM)

6. Neurodegenerative Disease Market Segmentation

• 6.1. Global Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parkinson's Disease
• Alzheimer's Disease
• Multiple Sclerosis
• Huntington Disease
• Amyotrophic Lateral Sclerosis
• 6.2. Global Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• N-methyl-D-aspartate Receptor antagonists
• Cholinesterase Inhibitors
• Dopamine Agonists
• Immunomodulatory Drugs
• Acetylcholinesterase (AChE) Inhibitors
• Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
• Catechol-O-Methyltransferase (COMT) Inhibitor
• Selective Serotonin Reuptake Inhibitor (SSRIs)
• Other Drug Types
• 6.3. Global Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Transdermal
• Other Routes Of Administration
• 6.4. Global Neurodegenerative Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Neurodegenerative Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Retail
• Online
• 6.6. Global Neurodegenerative Disease Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Parkinson's Disease
• Familial Parkinson's Disease
• Early-Onset Parkinson's Disease
• Parkinsonism
• 6.7. Global Neurodegenerative Disease Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Onset Alzheimer's Disease
• Late-Onset Alzheimer's Disease
• Familial Alzheimer's Disease (FAD)
• Inflammatory Subtype
• Non-Inflammatory Subtype
• Cortical Subtype
• 6.8. Global Neurodegenerative Disease Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinically Isolated Syndrome (CIS)
• Relapsing-Remitting MS (RRMS)
• Secondary Progressive MS (SPMS)
• Primary Progressive MS (PPMS)
• Progressive-Relapsing MS (PRMS)
• 6.9. Global Neurodegenerative Disease Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult-Onset Huntington's Disease
• Juvenile Huntington's Disease
• 6.10. Global Neurodegenerative Disease Market, Sub-Segmentation Of Amyotrophic Lateral Sclerosis (ALS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical ALS
• Limb-Onset ALS
• Bulbar-Onset ALS
• Respiratory-Onset ALS
• Primary Lateral Sclerosis (PLS)
• Progressive Muscular Atrophy (PMA)
• Juvenile ALS
• ALS-Parkinsonism-Dementia Complex (ALS-PDC)

7. Neurodegenerative Disease Market Regional And Country Analysis

• 7.1. Global Neurodegenerative Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurodegenerative Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurodegenerative Disease Market

• 8.1. Asia-Pacific Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurodegenerative Disease Market

• 9.1. China Neurodegenerative Disease Market Overview
• 9.2. China Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurodegenerative Disease Market

• 10.1. India Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurodegenerative Disease Market

• 11.1. Japan Neurodegenerative Disease Market Overview
• 11.2. Japan Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurodegenerative Disease Market

• 12.1. Australia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurodegenerative Disease Market

• 13.1. Indonesia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurodegenerative Disease Market

• 14.1. South Korea Neurodegenerative Disease Market Overview
• 14.2. South Korea Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurodegenerative Disease Market

• 15.1. Western Europe Neurodegenerative Disease Market Overview
• 15.2. Western Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurodegenerative Disease Market

• 16.1. UK Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurodegenerative Disease Market

• 17.1. Germany Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurodegenerative Disease Market

• 18.1. France Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurodegenerative Disease Market

• 19.1. Italy Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurodegenerative Disease Market

• 20.1. Spain Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurodegenerative Disease Market

• 21.1. Eastern Europe Neurodegenerative Disease Market Overview
• 21.2. Eastern Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurodegenerative Disease Market

• 22.1. Russia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurodegenerative Disease Market

• 23.1. North America Neurodegenerative Disease Market Overview
• 23.2. North America Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurodegenerative Disease Market

• 24.1. USA Neurodegenerative Disease Market Overview
• 24.2. USA Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurodegenerative Disease Market

• 25.1. Canada Neurodegenerative Disease Market Overview
• 25.2. Canada Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurodegenerative Disease Market

• 26.1. South America Neurodegenerative Disease Market Overview
• 26.2. South America Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurodegenerative Disease Market

• 27.1. Brazil Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurodegenerative Disease Market

• 28.1. Middle East Neurodegenerative Disease Market Overview
• 28.2. Middle East Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurodegenerative Disease Market

• 29.1. Africa Neurodegenerative Disease Market Overview
• 29.2. Africa Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurodegenerative Disease Market Competitive Landscape And Company Profiles

• 30.1. Neurodegenerative Disease Market Competitive Landscape
• 30.2. Neurodegenerative Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Neurodegenerative Disease Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Merck & Co. Inc.
• 31.5. Biogen Inc.
• 31.6. Neurocrine Biosciences Inc.
• 31.7. Alnylam Pharmaceuticals Inc.
• 31.8. Ionis Pharmaceuticals Inc.
• 31.9. Cassava Sciences Inc.
• 31.10. Denali Therapeutics Inc.
• 31.11. Voyager Therapeutics Inc.
• 31.12. AC Immune SA
• 31.13. Amylyx Pharmaceuticals Inc.
• 31.14. Sage Therapeutics Inc.
• 31.15. Alzheon Inc.

32. Global Neurodegenerative Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurodegenerative Disease Market

34. Recent Developments In The Neurodegenerative Disease Market

35. Neurodegenerative Disease Market High Potential Countries, Segments and Strategies

• 35.1 Neurodegenerative Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurodegenerative Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurodegenerative Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer